FGFR3 contributes to intestinal crypt cell growth arrest

被引:16
|
作者
Arnaud-Dabernat, Sandrine [1 ,2 ]
Yadav, Deepak [2 ]
Sarvetnick, Nora [2 ]
机构
[1] Univ Victor Segalen Bordeaux 2, INSERM U876, F-33076 Bordeaux, France
[2] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
关键词
D O I
10.1002/jcp.21401
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Fibroblast growth factors (FGFs) are important regulators of the dynamic development and turnover of tissues. Among FGF receptors, FGFR3 expression is confined in the intestinal crypts. We examined FGFR3-deficient mice and saw increased intestinal crypt depth but no change in villae length or in the distribution of differentiated intestinal cells, suggesting that the impact of lack of FGFR3 was limited to the progenitor cell compartment. Accordingly, enhancement of intestinal crypt proliferation was observed in FGFR3 mutant mice and interestingly, upon anti-FGFR3 antibody administration in wild type mice. Moreover, injection of FGF 18, a ligand of FGFR3, in wild type mice resulted in decreased cell proliferation within the intestinal crypts. In addition, we found that ERK level of activation was increased in FGFR3-deficient intestinal epithelium. In vitro studies showed that ERK, AKT and activation was regulated by FGFs and that ERK level of activation was inversely correlated to FGFR3 level of expression in the intestinal crypt cells. Furthermore, effects of FGF 18 on ERK and AKT activation paralleled FGFR3 effects on these intracellular targets. Our data indicate that FGF 18 and FGFR3 are involved, possibly as partners, in the control of intestinal precursor cell proliferation.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 50 条
  • [21] FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer
    Neuzillet, Yann
    van Rhijn, Bas W. G.
    Prigoda, Nadia L.
    Bapat, Bharati
    Liu, Liyang
    Bostrom, Peter J.
    Fleshner, Neil E.
    Gallie, Brenda L.
    Zlotta, Alexandre R.
    Jewett, Michael A. S.
    van der Kwast, Theo H.
    VIRCHOWS ARCHIV, 2014, 465 (02) : 207 - 213
  • [22] FGFR3 mutation is not the initiating mutation in Urothelial Cell Cancer
    Ahmad, I.
    Iwata, T.
    Wu, X. R.
    Leung, H. Y.
    Sansom, O. J.
    BJU INTERNATIONAL, 2009, 103 : 18 - 18
  • [24] FGFR3 as a therapeutic target in squamous cell lung carcinoma
    Liao, Rachel
    Hammerman, Peter
    Sivachenko, Andrey
    Greulich, Heidi
    Getz, Gad
    Liu, Qingsong
    Gray, Nathanael
    Meyerson, Matthew
    CANCER RESEARCH, 2012, 72
  • [25] FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer
    Yann Neuzillet
    Bas W. G. van Rhijn
    Nadia L. Prigoda
    Bharati Bapat
    Liyang Liu
    Peter J. Bostrom
    Neil E. Fleshner
    Brenda L. Gallie
    Alexandre R. Zlotta
    Michael A. S. Jewett
    Theo H. van der Kwast
    Virchows Archiv, 2014, 465 : 207 - 213
  • [26] Measuring the dimerization of FGFR3 transmembrane domain in cell membrane
    Chen, Lirong
    Krishnamoothy, Gayathri
    Cui, Jianmin
    Sept, David
    Hristova, Kalina
    BIOPHYSICAL JOURNAL, 2007, : 558A - 558A
  • [27] Signaling through FGFR3 is necessary for expansion of the epithelial stem cell compartment during normal intestinal development
    Vidrich, A
    Buzan, J
    Ilo, C
    Bradley, L
    Skaar, K
    Cohn, SM
    GASTROENTEROLOGY, 2003, 124 (04) : A22 - A22
  • [28] Fibroblast growth factor receptor 3 (FGFR3) expression in malignant lymphomas
    Larson, Andrew
    Cook, James R.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2008, 16 (04) : 322 - 325
  • [29] Study of FGFR3 Expression and FGFR3 Mutations in Molecular Subtypes of Muscle Invasive Bladder Cancer
    Kaushal, Seema
    Roy, Charli
    Seth, Amlesh
    Sahoo, Ranjit
    Batra, Atul
    Dinda, Amit
    LABORATORY INVESTIGATION, 2024, 104 (03) : S966 - S967
  • [30] Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
    Andrew J. Weickhardt
    David K. Lau
    Margeaux Hodgson-Garms
    Austen Lavis
    Laura J. Jenkins
    Natalia Vukelic
    Paul Ioannidis
    Ian Y. Luk
    John M. Mariadason
    BMC Cancer, 22